{
    "clinical_study": {
        "@rank": "106037", 
        "arm_group": [
            {
                "arm_group_label": "Chlorthalidone 12.5 mg", 
                "arm_group_type": "Experimental", 
                "description": "Chlorthalidone 12.5 mg by mouth once daily for 2 weeks"
            }, 
            {
                "arm_group_label": "Hydrochlorothiazide 25 mg", 
                "arm_group_type": "Experimental", 
                "description": "Hydrochlorothiazide 25 mg by mouth once daily for 2 weeks"
            }, 
            {
                "arm_group_label": "Aspirin 81 mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Aspirin 81 mg by mouth once daily for 2 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This will be a randomized, double-blinded, three-period crossover study of platelet\n      activation and aggregation in 30 non-smoking healthy volunteers comparing chlorthalidone\n      (CTD), hydrochlorothiazide (HCTZ), and aspirin (ASA; active control). The study hypothesis\n      is that CTD has different effects on platelet activation and aggregation than HCTZ."
        }, 
        "brief_title": "Chlorthalidone and HCTZ Impacts on Platelet Activation", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men or women age 19 or older\n\n          -  Not currently taking any routinely scheduled prescription or over the counter\n             medications or herbal supplements\n\n          -  No use of aspirin, clopidogrel, prasugrel, ticagrelor, cilostazol, dipyridamole,\n             NSAID medications, or herbal supplements within the previous 7 days and able to\n             refrain from use during the study period\n\n          -  Systolic blood pressure > 110 mmHg and diastolic blood pressure > 60 mmHg\n\n          -  Non-smoker\n\n        Exclusion Criteria:\n\n          -  Previous adverse reaction or allergy to HCTZ, CTD, or ASA\n\n          -  Severe sulfonamide hypersensitivity (anaphylaxis or Stevens-Johnson syndrome)\n\n          -  Diagnosis of any chronic disease or condition\n\n          -  History of gout or hyperuricemia\n\n          -  History of pancreatitis\n\n          -  History of systemic lupus erythematosus (SLE)\n\n          -  History of hypokalemia requiring treatment\n\n          -  Pregnant or planning to become pregnant during the study period\n\n          -  Breastfeeding\n\n          -  History of hypotension\n\n          -  History of gastrointestinal bleeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02100462", 
            "org_study_id": "13-16785"
        }, 
        "intervention": [
            {
                "arm_group_label": "Chlorthalidone 12.5 mg", 
                "intervention_name": "Chlorthalidone 12.5 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Hydrochlorothiazide 25 mg", 
                "intervention_name": "Hydrochlorothiazide 25 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Aspirin 81 mg", 
                "intervention_name": "Aspirin 81 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Aspirin", 
                "Chlorthalidone", 
                "Hydrochlorothiazide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hypertension", 
            "Platelet activation", 
            "Platelet aggregation", 
            "Chlorthalidone"
        ], 
        "lastchanged_date": "March 27, 2014", 
        "location": {
            "contact": {
                "email": "tammyburns@creighton.edu", 
                "last_name": "Tammy L Burns, PharmD, BCPS", 
                "phone": "402-717-0717"
            }, 
            "facility": {
                "address": {
                    "city": "Omaha", 
                    "country": "United States", 
                    "state": "Nebraska", 
                    "zip": "68178"
                }, 
                "name": "Creighton University"
            }, 
            "investigator": [
                {
                    "last_name": "Tammy L Burns, PharmD, BCPS", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Khalid Bashir, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Michael White, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Daniel E Hilleman, PharmD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Venkata M Alla, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Venkata Andukuri, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Evaluation of Platelet Effects of Chlorthalidone and Hydrochlorothiazide", 
        "overall_contact": {
            "email": "tammyburns@creighton.edu", 
            "last_name": "Tammy L Burns, PharmD", 
            "phone": "402-717-0717"
        }, 
        "overall_contact_backup": {
            "email": "sandrabyers@creighton.edu", 
            "last_name": "Sandy Byers, RN", 
            "phone": "402-717-0717"
        }, 
        "overall_official": {
            "affiliation": "Creighton University", 
            "last_name": "Khalid Bashir, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint for this study will be the change in mean fluorescence intensity (MFI) of the platelet activation marker PAC-1 due to HCTZ, CTD, and aspirin.", 
            "measure": "Change in mean fluorescence intensity of PAC-1", 
            "safety_issue": "No", 
            "time_frame": "2 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02100462"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change in platelet expression of CD62P (p-selectin) in response to CTD, HCTZ, and ASA.", 
                "measure": "Change in CD62P expression", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "description": "Change in platelet aggregation measured by flow cytometry in response to CTD, HCTZ, and ASA", 
                "measure": "Change in platelet aggregation", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }
        ], 
        "source": "Creighton University", 
        "sponsors": {
            "collaborator": {
                "agency": "Dialysis Clinic, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Creighton University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}